Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market by Drug Classes, Clinical Pipeline and Forecast to 2021, New Report by iHealthcareAnalyst, Inc.
Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market by Drug Classes (Angiogenesis Inhibitors – Avastin, Cyramza; Epidermal Growth Factor Receptor Blockers – Tarceva, Gilotrif, Iressa; Folate Antimetabolites – Alimta; Kinase Inhibitors – Xalkori, Zykadia; Microtubule Stabilizers – Abraxane, Docetaxel; and PD-1/ PD-L1 Inhibitors – Opdivo, Keytruda), and Clinical Pipeline (Avelumab, MPDL3280A, MEDI4736, Abemaciclib)
Maryland Heights, MO, May 06, 2017 --(PR.com)-- Non-small cell lung cancer (NSCLC) is the most common type of lung cancer (about 85% of lung cancers) and it usually grows and spreads more slowly than small cell lung cancer. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer. Non-small cell lung cancer is a major type of lung cancer, accounting about 80% to 90% of the total lung cancers, with one of the highest mortality rates. Treatment of NSCLC depends on the stage of cancer, type of NSCLC, type of mutation gene such as epidermal growth factor receptor (EGFR) gene and anaplastic lymphoma kinase (ALK) gene, and patient’s general health.
Browse Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market by Drug Classes (Angiogenesis Inhibitors – Avastin, Cyramza; Epidermal Growth Factor Receptor Blockers – Tarceva, Gilotrif, Iressa; Folate Antimetabolites – Alimta; Kinase Inhibitors – Xalkori, Zykadia; Microtubule Stabilizers – Abraxane, Docetaxel; and PD-1/ PD-L1 Inhibitors – Opdivo, Keytruda), and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs (Avelumab, MPDL3280A, MEDI4736, Abemaciclib) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/non-small-cell-lung-cancer-therapeutics-market/
The global non-small cell lung cancer therapeutics market report estimates the market size (Revenue USD million - 2014 to 2021) for key market segments based on the drug classes (angiogenesis inhibitors – Avastin, Cyramza; epidermal growth factor receptor blockers – Tarceva, Gilotrif, Iressa; Folate antimetabolites – Alimta; kinase inhibitors – Xalkori, Zykadia; microtubule stabilizers – Abraxane, Docetaxel; and PD-1/ PD-L1 inhibitors – Opdivo, Keytruda), clinical pipeline analysis of phase 1, 2 and 3 drugs (Avelumab, MPDL3280A, MEDI4736, Abemaciclib, etc.), and forecasts growth trends (CAGR% - 2017 to 2021).
The global non-small cell lung cancer therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global non-small cell lung cancer therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global non-small cell lung cancer therapeutics market and included in this report are AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genentech (Roche), Novartis AG, Pfizer, Inc., and Sun Pharmaceutical Industries Ltd.
1. Drug Class
1.1. Angiogenesis Inhibitor
1.1.1. Avastin (Bevacizumab)
1.1.2. Cyramza (Ramucirumab)
1.2. Epidermal Growth Factor Receptor Blocker
1.2.1. Tarceva (Erlotinib)
1.2.2. Gilotrif (Afatinib)
1.2.3. Iressa (Gefitinib)
1.3. Folate Antimetabolites
1.3.1. Alimta (Pemetrexed)
1.4. Kinase Inhibitor
1.4.1. Xalkori (Crizotinib)
1.4.2. Zykadia (Ceritinib)
1.5. Microtubule Stabilizer
1.5.1. Abraxane (Paclitaxel Protein Bound)
1.5.2. Docetaxel
1.6. PD-1/ PD-L1 Inhibitor
1.6.1. Opdivo (Nivolumab)
1.6.2. Keytruda (Pembrolizumab)
2. Clinical Pipeline Analysis (Phase 1, 2 and 3)
2.1. Avelumab
2.2. MPDL3280A
2.3. MEDI4736
2.4. Abemaciclib
2.5. Others
2.6. Pipeline Analysis (Phase 1 and 2)
3. Company Profiles
3.1. AstraZeneca plc.
3.2. Boehringer Ingelheim
3.3. Bristol-Myers Squibb
3.4. Celgene Corporation
3.5. Eli Lilly & Co.
3.6. F. Hoffmann-La Roche Ltd.
3.7. GlaxoSmithKline PLC
3.8. Pfizer, Inc.
3.9. Sun Pharmaceutical Industries Ltd.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/non-small-cell-lung-cancer-therapeutics-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Browse Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market by Drug Classes (Angiogenesis Inhibitors – Avastin, Cyramza; Epidermal Growth Factor Receptor Blockers – Tarceva, Gilotrif, Iressa; Folate Antimetabolites – Alimta; Kinase Inhibitors – Xalkori, Zykadia; Microtubule Stabilizers – Abraxane, Docetaxel; and PD-1/ PD-L1 Inhibitors – Opdivo, Keytruda), and Clinical Pipeline Analysis of Phase 1, 2 and 3 Drugs (Avelumab, MPDL3280A, MEDI4736, Abemaciclib) and Forecast 2017-2021 at https://www.ihealthcareanalyst.com/report/non-small-cell-lung-cancer-therapeutics-market/
The global non-small cell lung cancer therapeutics market report estimates the market size (Revenue USD million - 2014 to 2021) for key market segments based on the drug classes (angiogenesis inhibitors – Avastin, Cyramza; epidermal growth factor receptor blockers – Tarceva, Gilotrif, Iressa; Folate antimetabolites – Alimta; kinase inhibitors – Xalkori, Zykadia; microtubule stabilizers – Abraxane, Docetaxel; and PD-1/ PD-L1 inhibitors – Opdivo, Keytruda), clinical pipeline analysis of phase 1, 2 and 3 drugs (Avelumab, MPDL3280A, MEDI4736, Abemaciclib, etc.), and forecasts growth trends (CAGR% - 2017 to 2021).
The global non-small cell lung cancer therapeutics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global non-small cell lung cancer therapeutics market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global non-small cell lung cancer therapeutics market and included in this report are AstraZeneca plc, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, Genentech (Roche), Novartis AG, Pfizer, Inc., and Sun Pharmaceutical Industries Ltd.
1. Drug Class
1.1. Angiogenesis Inhibitor
1.1.1. Avastin (Bevacizumab)
1.1.2. Cyramza (Ramucirumab)
1.2. Epidermal Growth Factor Receptor Blocker
1.2.1. Tarceva (Erlotinib)
1.2.2. Gilotrif (Afatinib)
1.2.3. Iressa (Gefitinib)
1.3. Folate Antimetabolites
1.3.1. Alimta (Pemetrexed)
1.4. Kinase Inhibitor
1.4.1. Xalkori (Crizotinib)
1.4.2. Zykadia (Ceritinib)
1.5. Microtubule Stabilizer
1.5.1. Abraxane (Paclitaxel Protein Bound)
1.5.2. Docetaxel
1.6. PD-1/ PD-L1 Inhibitor
1.6.1. Opdivo (Nivolumab)
1.6.2. Keytruda (Pembrolizumab)
2. Clinical Pipeline Analysis (Phase 1, 2 and 3)
2.1. Avelumab
2.2. MPDL3280A
2.3. MEDI4736
2.4. Abemaciclib
2.5. Others
2.6. Pipeline Analysis (Phase 1 and 2)
3. Company Profiles
3.1. AstraZeneca plc.
3.2. Boehringer Ingelheim
3.3. Bristol-Myers Squibb
3.4. Celgene Corporation
3.5. Eli Lilly & Co.
3.6. F. Hoffmann-La Roche Ltd.
3.7. GlaxoSmithKline PLC
3.8. Pfizer, Inc.
3.9. Sun Pharmaceutical Industries Ltd.
To request Table of Contents and Sample Pages of this report visit:
https://www.ihealthcareanalyst.com/report/non-small-cell-lung-cancer-therapeutics-market/
About Us
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
Contact Us
iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: sales@ihealthcareanalyst.com
Website: https://www.ihealthcareanalyst.com
Contact
iHealthcareAnalyst, Inc.
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Ana Aitawa
(314) 500-7508
https://www.ihealthcareanalyst.com/
Contact
Categories